Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 133-137, May 2005

Prevalence of antiphospholipid antibodies is not different in Chilean diabetic patients and normal individuals

  • Iván G. Palomo

      Affiliations

    • Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile
  • ,
  • Verónica E. Mujica

      Affiliations

    • Servicio de Medicina (Medical Service), Hospital Regional de Talca, Talca, Chile
  • ,
  • Marcelo L. Alarcón

      Affiliations

    • Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile
  • ,
  • Jaime G. Pereira

      Affiliations

    • Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
  • ,
  • Marcela R. Vásquez

      Affiliations

    • Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile
    • Corresponding Author InformationCorresponding author. Tel.: +56 71 200494; fax: +56 71 200488.

Received 16 July 2003; received in revised form 3 September 2004; accepted 21 September 2004.

Abstract 

Diabetes mellitus (DM) is complicated by vascular and neurological events. Antiphospholipid (aPL) antibodies have already been associated with many clinical conditions, including venous and arterial thrombosis, as well as recurrent fetal loss. However, a significant association between aPL antibodies and DM has not been widely reported yet. In the present study, we investigated the prevalence of aPL antibodies in diabetic patients. This study included 100 Chilean diabetic patients (67 of them with some complications and 33 without complications; 28 with Type 1 and 72 with Type 2 DM) and 100 healthy blood donor controls. Each sample was analyzed for IgG, IgM and IgA anticardiolipin (aCL), anti-β2 glycoprotein I (anti-β2GPI), antiprothrombin (aPT) antibodies, and lupus anticoagulant (LA). Fourteen out of 100 (14%) diabetic patients presented some type of aPL antibodies. Four patients were positive for aCL antibodies, two for anti-β2GPI antibodies, and nine for aPT antibodies. All patients were LA negative. The incidence of different isotypes was similar in each of the aPL antibodies studied, and their activities were low. No significant correlation was observed between aPL antibodies and vascular complications.

Keywords: Antiphospholipid antibodies, Diabetes mellitus

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1056-8727(04)00100-X

doi:10.1016/j.jdiacomp.2004.09.004

Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 133-137, May 2005